- Home
- AIEV vs GDTC Comparison
AIEV vs GDTC Comparison
Compare AIEV & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIEV
- GDTC
- Stock Information
- Founded
- AIEV 2011
- GDTC 2018
- Country
- AIEV United States
- GDTC Singapore
- Employees
- AIEV N/A
- GDTC 34
- Industry
- AIEV Blank Checks
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- AIEV Finance
- GDTC Health Care
- Exchange
- AIEV Nasdaq
- GDTC Nasdaq
- Market Cap
- AIEV 25.8M
- GDTC 25.7M
- IPO Year
- AIEV N/A
- GDTC 2023
- Fundamental
- Price
- AIEV $0.29
- GDTC $2.20
- Analyst Decision
- AIEV
- GDTC Buy
- Analyst Count
- AIEV 0
- GDTC 1
- Target Price
- AIEV N/A
- GDTC $5.00
- AVG Volume (30 Days)
- AIEV 116.1K
- GDTC 13.3K
- Earning Date
- AIEV 11-14-2024
- GDTC 01-01-0001
- Dividend Yield
- AIEV N/A
- GDTC N/A
- EPS Growth
- AIEV N/A
- GDTC N/A
- EPS
- AIEV N/A
- GDTC N/A
- Revenue
- AIEV N/A
- GDTC $330,254.00
- Revenue This Year
- AIEV N/A
- GDTC $14.71
- Revenue Next Year
- AIEV N/A
- GDTC N/A
- P/E Ratio
- AIEV N/A
- GDTC N/A
- Revenue Growth
- AIEV N/A
- GDTC N/A
- 52 Week Low
- AIEV $0.27
- GDTC $1.20
- 52 Week High
- AIEV $12.12
- GDTC $5.50
- Technical
- Relative Strength Index (RSI)
- AIEV N/A
- GDTC 49.23
- Support Level
- AIEV N/A
- GDTC $1.88
- Resistance Level
- AIEV N/A
- GDTC $2.35
- Average True Range (ATR)
- AIEV 0.00
- GDTC 0.36
- MACD
- AIEV 0.00
- GDTC -0.05
- Stochastic Oscillator
- AIEV 0.00
- GDTC 37.00
About AIEV Thunder Power Holdings Inc. Common Stock
Thunder Power Holdings Inc is engaged in the design and development of high-performance electric vehicles.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.